We have stayed out of stock trades of companies whose stock has moved directly related to new vaccine and therapeutic activities related to Coronavirus because we try to stay out of hype trades. We are digging deeper into opportunities for companies who have had success in developing therapies and vaccines for viruses. For example, we are watching Novavax's expected report out later this month of its phase 3 trial for its latest attempt at an influenza vaccine. You can find more information about this readout by searching our Catalyst Database or on our NanoFlu/influenza page. However, the company has not had great success with its vaccine development and unless our deeper diligence tells us otherwise, we only have a small investment in one of our accounts.
With respect to the broader market, every stock has been effected by the current Coronavirus pandemic. For the markets and more importantly, world health, it would be excellent if the warm humid months give us a break from the pandemic. In the U.S., that would give us more time to develop vaccines and test treatments before the next outbreak season.